Landos Biopharma: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Landos Biopharma (NASDAQ:LABP) reported its Q3 earnings, missing estimated earnings by 6.82% with an EPS of $-0.94 versus an estimate of $-0.88. Revenue was down $0 from the same period last year. Last quarter, the company beat on EPS by $0.47, which was followed by a 1.22% drop in the share price the next day.
November 09, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Landos Biopharma's Q3 earnings missed estimates, which could negatively impact the stock price in the short term.
Landos Biopharma missed its Q3 earnings estimates, which is typically seen as a negative signal by investors and could lead to a decrease in the stock price. Additionally, the company's revenue was down from the same period last year, which could further contribute to a negative sentiment among investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100